Meta-analysis of 11 studies involving 427 subjects reveals GLP-1 receptor agonists significantly increase total and free testosterone levels plus gonadotropins in overweight men, with effects occurring independently of weight loss. This suggests direct action on the hypothalamus-pituitary-testis axis rather than purely metabolic benefits. Both GLP-1 agonists and SGLT2 inhibitors improved erectile function outcomes alongside expected improvements in body composition and metabolic profiles.
This finding reframes these diabetes medications as potential dual-purpose therapeutics addressing both metabolic dysfunction and age-related hormonal decline. The testosterone-boosting effect independent of weight loss is particularly significant, as it suggests these drugs could benefit men with hypogonadism who aren't necessarily obese. However, testosterone replacement therapy still outperformed GLP-1 agonists for orgasm and sexual satisfaction domains, indicating combination therapy might be optimal. The research landscape around these blockbuster drugs continues expanding beyond their original diabetes and weight-loss applications, though the small sample sizes and limited SGLT2 inhibitor data warrant cautious interpretation until larger studies confirm these hormonal benefits.